Lovastatin: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #132 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Statins]] | |||
[[Category:Lipid-lowering agents]] | |||
Latest revision as of 10:43, 23 May 2026
Lovastatin
Altoprev (ER), Mevacor (discontinued US); mostly generic
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Common uses
Hyperlipidemia0, Cardiovascular risk reduction0
Pharmacy
Starting dose
20 mg PO once daily with the evening meal; titrate to 40-80 mg/d
Preparations
10, 20, 40 mg tablets; 20, 40, 60 mg ER tablets
US FDA Max
80 mg/d (40 mg/d if combined with diltiazem, verapamil, danazol; lower limits with various interactions)
Pharmacology
Routes
Oral
Onset
LDL lowering at 2 weeks, max by 4 weeks
Duration
24 hours
Half-life
~2-4 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect 24 hours via target turnover[2]
Bioavailability
<5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)[2]
Pregnancy
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Lovastatin is an inactive lactone prodrug hydrolyzed to its active β-hydroxy acid, a competitive HMG-CoA reductase inhibitor.0 Originally derived from Aspergillus terreus; the first statin approved for clinical use (1987). CYP3A4 substrate with extensive drug-interaction profile similar to simvastatin's. SLCO1B1 polymorphism affects exposure; CPIC guidance is most actionable for simvastatin[1].
References
- ↑ CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 and Statin-Associated Musculoskeletal Symptoms, 2022. https://cpicpgx.org/guidelines/cpic-guideline-for-simvastatin-and-slco1b1/
- ↑ 2.0 2.1 FDA Prescribing Information, Altoprev (lovastatin ER), Shionogi, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021316s016lbl.pdf